Rigel Pharmaceuticals (RIGL) Short-term Investments (2010 - 2026)

Rigel Pharmaceuticals has reported Short-term Investments for 17 years, with the latest figure at $122.3 million in Q1 2026.

• For the quarter ending Q1 2026, Short-term Investments rose 289.76% year-over-year to $122.3 million; the trailing twelve-month figure through Mar 2026 stood at $122.3 million (up 289.76% YoY), and the FY2025 full-year result was $114.4 million, up 455.89% from the prior year.
• Short-term Investments for Q1 2026 stood at $122.3 million, up from $114.4 million in the prior quarter.
• The five-year high for Short-term Investments was $122.3 million in Q1 2026, with the low at $9.4 million in Q3 2024.
• Average Short-term Investments over 5 years is $46.1 million, with a median of $31.4 million recorded in 2025.
• Year-over-year, Short-term Investments plunged 77.82% in 2023 and soared 840.45% in 2025.
• Tracing RIGL's Short-term Investments over 5 years: stood at $33.7 million in 2022, then retreated by 28.45% to $24.1 million in 2023, then dropped by 14.79% to $20.6 million in 2024, then soared by 455.89% to $114.4 million in 2025, then grew by 6.91% to $122.3 million in 2026.
• The last three Short-term Investments figures came in at $122.3 million (Q1 2026), $114.4 million (Q4 2025), and $88.6 million (Q3 2025), per Business Quant data.

Peer Comparison